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Dr R. Dion (Genk, Belgium). Dr Flynn, I would like to congrat-
ulate you for the quality of your presentation, and the authors andThe Journal of Thoracic and Cfriends from the Cleveland Clinic have to be commended for an
original pilot study trying to elucidate the relation between wall
motion abnormality and scarring and return of MR. CMR was
used, which is certainly very elaborate and time-consuming; there-
fore, one should not underestimate the task of applying CMR and
analyzing it in 29 patients.
The main finding of this study is that extensive scarring, and se-
vere wall motion abnormality to a lesser extent because it is less sig-
nificant in the region of the posterior papillary muscle, correlates
with the return of MR.
My first question concerns the preoperative myocardial infarc-
tion. All 29 patients had a history of myocardial infarction. Could
you specify in which coronary territory? Was it mainly in the region
of the right coronary and the circumflex, as expected, and did it al-
ways correlate with the site of scarring on CMR?
Dr Flynn. Thank you for your kind comments and your good
questions. First, the most predominant area of infarction was in-
ferior, in the right coronary territory. We did not investigate
whether the degree of CMR-assessed scarring correlated with
the presence of myocardial ischemia. We do not have evidence
on that.
Dr Dion. I ask because the LAD mean wall motion was grade
2.1. It was grade 2.3 for the RCA and the posterior papillary mus-
cle, but it was only grade 1.6 for the circumflex and the anterior
papillary muscle. So there was more wall motion abnormality in
the anterior part of the heart than in the territory of the circumflex.
There was also more scar in the LAD than in LCx and in the anterior
papillary muscle territory, which is a bit surprising for me, because
I would have expected more scarring in the territory of the circum-
flex than in the LAD.
However, in the Discussion you state ‘‘the posterolateral wall,
which is predominantly supplied by the LCx, has less collateral cir-
culation in patients with diffuse 3-system coronary artery disease,
making it more prone to scarring, with resulting high correlation be-
tween amount of scarring and regional wall motion abnormalities.’’
But again, the mean scar score is less than 2 in the circumflex ter-
ritory. Can you elaborate on that?
Dr Flynn. Indeed. We feel that the most relevant territory is
possibly that of the right coronary, and to relate this to scarring
or dysfunction in the posterior papillary and the fact that it may
be supplied by 2 territories, as you are aware: if there is disease
or coronary disease related to both of those territories, these are
the patients who are at risk and who possibly have a greater
degree of scarring in the posterior papillary region. And these
are possibly the patients then, as we have demonstrated here,
who have a higher rate of recurrence of ischemic MR after
surgery.
Dr Dion. Thank you. Forty-four percent of the patients had
a scar of more than 25% in the posterior papillary muscle, but
the posterior papillary was attributed 2 segments and the anterior
papillary muscle, only 1 segment. Could it have influenced the
results? Why did you decide that the anterior papillary muscle
would be 1 segment and the posterior papillary muscle 2 seg-
ments?
Dr Flynn. Well, we know from science and nature that the pos-
terior papillary is related to 2 coronary territories. We feel that dis-
ease involving both of those coronary territories makes the
posterior papillary more at risk for infarction and a greater determi-
nant of dysfunction.ardiovascular Surgery c Volume 137, Number 5 1069
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DDrDion. Thank you. I am surprised by the relatively high rate of
recurrent MR at 6 months. It is probably explained by the fact that
the choice of the procedure was left at the discretion of the surgeon,
but, on the other hand, it allowed your group to perform this study
with ‘‘only’’ 29 patients. What do you think about the temporal pat-
tern of postoperative MR in 2 phases? I found it very interesting and
very intriguing. Why such an increase in the first 3 months and after
that, stabilization? How do you interpret that?
Dr Flynn. As you are aware, this represents a valvular approach
to a ventricular problem, and this may reflect the fact that annulo-
plasty in these patients, particularly those who got scarring in
that papillary region, may not be the appropriate approach for these
patients. I think to study the overall temporal occurrence of MR was
not within the remit of this study. It wasn’t designed for that pur-
pose; it wasn’t powered for that purpose. So we have not studied
or assessed the temporal degeneration of MR.
Dr. Dion. And finally, I found your conclusion quite severe for
restrictive mitral annuloplasty. You state, ‘‘CABG and concurrent
mitral annuloplasty are ineffective for severe scarring in the region
of the posterior papillary muscle.’’ But even in your setup, 30% of
the patients with severe scarring of the posterior papillary muscle
had no recurrent MR, and 15% with little scarring in the posterior
papillary muscle had recurrent MR. Don’t you think that, besides
the scarring and the wall motion abnormality, you should have
taken into account the LV dilatation? Maybe there is a relation be-
tween the extent of scarring and the LV dilatation, which might ex-
plain that without scarring and with LV dilatation you could have
recurrent MR.
Dr Flynn. I think your comments are well received. I think these
are different ways of looking at very sick patients. These are differ-
ent means of looking at severe LV dysfunction. Yes, indeed, LV
end-diastolic diameter is 1 parameter that can be used. Our mean
LV end-diastolic diameter was 62 mm, but we were unable to study
whether that was a determinant of recurrence of MR or not. You
will remember that our LV ejection fraction mean was 22%.
They were all under 30%. So I think this is perhaps a different
means of looking at a very sick patient group.
Dr Dion. Sure. But if you use CMR, it would probably be inter-
esting as well to also look also at the dimensions: obviously you
plan to extend this type of segmental analysis with CMR, which
is a very time-consuming and elaborate task. And if you were
able to link some of your segmental analysis to global LV dimen-
sion, which is easier to measure, it might simplify your work.
Again, I appreciate very much to review this paper and I congrat-
ulate you for an excellent presentation. I thank the Society for the
privilege of discussing it.
Dr Flynn. Thank you, Professor Dion. Thank you very much.1070 The Journal of Thoracic and Cardiovascular SuDr D. Adams (New York). Michael, that was an elegant study
and it is important, and it actually correlates with some of your
previous work from your institution about the importance of via-
ble myocardium in predicting a good result after ischemic repair.
So it is logical that a scar burden would also predict failure, and I
think that is important, particularly in your subgroup, which I
would emphasize for the audience had a very low ejection frac-
tion. So these are difficult patients to make decisions about
whether to operate and what to do. This spectrum of ischemic pa-
tients is very difficult.
My question relates to your specific ring strategy, and I think to
understand any results in restrictive disease, we don’t have data, we
don’t have randomized trials, but I just want to understand, were
they downsized, were they rigid, were they complete, and did
your ring strategy evolve over time? This is a relatively current
study, end point 2001 to 2006, and did that make a difference?
Did you see any patterns you can share with us?
Dr Flynn. First, thank you for your comments and your very
good questions. This was a very small study group. There were 7
patients who had complete rings, 22 who had partial rings. Again,
this study was not designed to compare one ring to another. We
found no difference in the rate of recurrence of MR between the
7 patients with a complete versus the 22 who had a partial ring.
We were unable to assess that.
Your second question regarding the method of downsizing, that
was surgeon-specific. There are different methods used at our insti-
tution depending upon the surgeon.
Dr L. Cohn (Boston, Mass). Excellent data presented beauti-
fully. This is similar to what Dr Dor has been advocating for
some time. Magnetic resonance imaging is something that cardiac
surgeons should really adopt, and I suspect that you agree with
that.
Any suggestions based on these data for more effective surgical
therapy? Based on what you have presented to us, have you and
your colleagues at the Cleveland Clinic decided on a more effective
or more strategic way to treat these patients? And what are your cur-
rent, shall we say, thoughts on recent surgical therapy about this
now, based on the data that you presented to us?
Dr Flynn. Dr Cohn, thank you very much for your kind com-
ments. I think this is a very difficult area and a very difficult patient
group. There are various thoughts and theories. I think the thought
of replacing the mitral valve in this patient group with a tissue valve
is one concept, then ventricular restoration is another possibility.
Again, it depends on the severity of LV dysfunction as to how
one would address the ventricular problems. There are other op-
tions. None of them are ideal. As you are aware, it is a very difficult
problem as to how to approach this.rgery c May 2009
